Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Travoprost
Drug ID BADD_D02265
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
Indications and Usage Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Marketing Status Prescription; Discontinued
ATC Code S01EE04
DrugBank ID DB00287
KEGG ID D01964
MeSH ID D000069557
PubChem ID 5282226
TTD Drug ID D09CZA
NDC Product Code 54893-0020; 40016-006; 0078-0946; 82231-114; 45542-1162; 38779-3063; 64181-0028; 63629-8839; 65035-131; 65129-1207; 61556-040; 0781-6185; 24002-0022; 68245-0003; 63190-0350; 60505-0593; 63629-8840; 55359-540
Synonyms Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221
Chemical Information
Molecular Formula C26H35F3O6
CAS Registry Number 157283-68-6
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain08.01.08.004--
Palpitations02.01.02.0030.000791%
Panophthalmitis06.04.05.005--Not Available
Peptic ulcer07.04.07.001--Not Available
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Photophobia17.17.02.006; 06.01.01.0040.002770%
Photopsia17.17.01.006; 06.02.06.004--
Prostatic disorder21.04.01.001--Not Available
Prostatic specific antigen increased13.22.01.001--Not Available
Pruritus23.03.12.001--
Punctate keratitis06.04.02.0030.000791%Not Available
Rash23.03.13.001--Not Available
Retinal detachment06.09.03.003; 12.01.04.0040.001583%
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Retinal pigmentation06.09.03.008--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Scab23.03.03.004--Not Available
Sinusitis11.01.13.005; 22.07.03.007--
Skin discolouration23.03.03.0050.001583%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000791%Not Available
Skin hyperpigmentation23.05.01.003--
Skin irritation23.03.04.0090.000791%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tachycardia02.03.02.007--Not Available
Tenderness08.01.08.005--Not Available
Throat irritation22.02.05.013; 07.05.03.0040.000791%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Transient ischaemic attack24.04.06.005; 17.08.04.0010.000791%
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages